VANCOUVER, June 21 /CNW/ - Biotech Holdings (the "Company", TSXV: BIO;
OTC BB: BIOHF) reports that the Mexican Diabetes Federation has given
Biotech's "Sucanon" diabetes drug its support in an overview of diabetic drugs
published in the May-June 2007 issue of Diabetes Hoy, the Diabetic
Federation's scientific and medical magazine for doctors and other health
The overview of diabetic drugs, written by Dr. Roberto Cepeda Gonzalez,
Medical Director of the Specialized Center for Diabetes, in Mexico City, notes
that Sucanon falls in a category of diabetic drugs known as "insulin
sensitizers" for their action in making the body's cells more sensitive to
circulating insulin. The review (see Endorsements at
http://www.sucanonhealth.com/section.asp?pageid=4107) notes that the most
widely used insulin sensitizers belong to a family of drugs known as
thiazolidinediones or glitazones.
The glitazone drugs, the review notes, have a history of problems in
contrast with Sucanon which, clinical studies have indicated, is very safe.
The review notes that Sucanon does not have any of the hepatotoxicity or
liver-damage risks of the glitazone drugs. The first glitazone, troglitazone
was approved in 1998 but was withdrawn shortly thereafter. Two additional
glitazones - rosiglitazone and pioglitazone - have recently been targeted with
a "black box" warning by the U.S. FDA due to concerns related to cardiac risk
when taking these drugs (see http://www.msnbc.msn.com/id/19090626/).
The review in Diabetes Hoy also notes that another widely used Type II
Diabetes medication, metformin, presents risks for patients with compromised
kidney function, frequently a symptom of Type II Diabetes.
Sucanon, which received regulatory approval in Mexico in 2004, is widely
sold in that country on a non-prescription basis through a range of retailers
including Costco and Walmart.
Sucanon is now also available without prescription to diabetics in
countries worldwide, including the U.S. and Canada, which permit import of
otherwise-unavailable drugs for direct personal use. To order Sucanon, see
This release has been approved by the Board of Directors of Biotech
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
Robert B. Rieveley, Pres.
On behalf of the Board of Directors
Any statements made in this release that are not based on historical fact
are forward-looking statements. Any forward-looking statements made in this
release represent management's best judgement as to what may occur in the
future. However, actual outcome and results are not guaranteed and are subject
to certain risks, uncertainties and assumptions and may differ materially from
what is expressed.
If you wish to be removed from Biotech Holdings' email news distribution
list, please reply by email, putting "remove" in the subject line.
For further information:
For further information: Austin Rand at Biotech Holdings, 1-888-216-1111
(toll-free) 8 a.m. to 4 p.m. Pacific time. For background information on
Biotech Holdings, or to receive news updates, see www.biotechltd.com. The
company can be reached by calling (604) 295-1119